S&P 500   3,621.63 (-0.46%)
DOW   29,638.64 (-0.91%)
QQQ   299.24 (+0.08%)
AAPL   120.11 (+3.02%)
MSFT   213.48 (-0.81%)
FB   275.71 (-0.76%)
GOOGL   1,751.90 (-1.97%)
AMZN   3,164.83 (-0.95%)
TSLA   569.43 (-2.79%)
NVDA   534.32 (+0.73%)
BABA   263.25 (-4.79%)
CGC   28.86 (-0.48%)
GE   10.27 (-1.25%)
MU   64.15 (-0.12%)
AMD   92.52 (+6.11%)
T   28.77 (-0.90%)
NIO   50.91 (-5.72%)
F   9.06 (-0.33%)
ACB   11.73 (+12.03%)
NFLX   489.99 (-0.28%)
BA   210.77 (-2.65%)
GILD   60.43 (+0.67%)
DIS   147.57 (+0.30%)
S&P 500   3,621.63 (-0.46%)
DOW   29,638.64 (-0.91%)
QQQ   299.24 (+0.08%)
AAPL   120.11 (+3.02%)
MSFT   213.48 (-0.81%)
FB   275.71 (-0.76%)
GOOGL   1,751.90 (-1.97%)
AMZN   3,164.83 (-0.95%)
TSLA   569.43 (-2.79%)
NVDA   534.32 (+0.73%)
BABA   263.25 (-4.79%)
CGC   28.86 (-0.48%)
GE   10.27 (-1.25%)
MU   64.15 (-0.12%)
AMD   92.52 (+6.11%)
T   28.77 (-0.90%)
NIO   50.91 (-5.72%)
F   9.06 (-0.33%)
ACB   11.73 (+12.03%)
NFLX   489.99 (-0.28%)
BA   210.77 (-2.65%)
GILD   60.43 (+0.67%)
DIS   147.57 (+0.30%)
S&P 500   3,621.63 (-0.46%)
DOW   29,638.64 (-0.91%)
QQQ   299.24 (+0.08%)
AAPL   120.11 (+3.02%)
MSFT   213.48 (-0.81%)
FB   275.71 (-0.76%)
GOOGL   1,751.90 (-1.97%)
AMZN   3,164.83 (-0.95%)
TSLA   569.43 (-2.79%)
NVDA   534.32 (+0.73%)
BABA   263.25 (-4.79%)
CGC   28.86 (-0.48%)
GE   10.27 (-1.25%)
MU   64.15 (-0.12%)
AMD   92.52 (+6.11%)
T   28.77 (-0.90%)
NIO   50.91 (-5.72%)
F   9.06 (-0.33%)
ACB   11.73 (+12.03%)
NFLX   489.99 (-0.28%)
BA   210.77 (-2.65%)
GILD   60.43 (+0.67%)
DIS   147.57 (+0.30%)
S&P 500   3,621.63 (-0.46%)
DOW   29,638.64 (-0.91%)
QQQ   299.24 (+0.08%)
AAPL   120.11 (+3.02%)
MSFT   213.48 (-0.81%)
FB   275.71 (-0.76%)
GOOGL   1,751.90 (-1.97%)
AMZN   3,164.83 (-0.95%)
TSLA   569.43 (-2.79%)
NVDA   534.32 (+0.73%)
BABA   263.25 (-4.79%)
CGC   28.86 (-0.48%)
GE   10.27 (-1.25%)
MU   64.15 (-0.12%)
AMD   92.52 (+6.11%)
T   28.77 (-0.90%)
NIO   50.91 (-5.72%)
F   9.06 (-0.33%)
ACB   11.73 (+12.03%)
NFLX   489.99 (-0.28%)
BA   210.77 (-2.65%)
GILD   60.43 (+0.67%)
DIS   147.57 (+0.30%)
Log in
NASDAQ:OMER

Omeros Stock Forecast, Price & News

$11.51
-0.23 (-1.96 %)
(As of 11/30/2020 03:50 PM ET)
Add
Compare
Today's Range
$11.32
Now: $11.51
$11.72
50-Day Range
$10.14
MA: $11.07
$11.94
52-Week Range
$8.50
Now: $11.51
$25.46
Volume4,557 shs
Average Volume890,760 shs
Market Capitalization$709.61 million
P/E RatioN/A
Dividend YieldN/A
Beta1.64
Omeros Corporation, a biopharmaceutical company, discovers, develops, and commercializes small-molecule and protein therapeutics, and orphan indications targeting inflammation, complement-mediated diseases, disorders of the central nervous system (CNS), and immune-related diseases. It provides OMIDRIA for use in cataract surgery or intraocular lens replacement in the United States. The company's clinical programs include Narsoplimab (OMS721/MASP-2) that is in Phase III clinical trial for hematopoietic stem-cell transplant-associated thrombotic microangiopath, immunoglobulin A nephropathy, and atypical hemolytic uremic syndrome; and Phase II clinical trial to treat lupus nephritis and other renal diseases. Its clinical programs also consists of PPAR? (OMS405) that is in Phase II clinical trial to treat opioid and nicotine addiction; and PDE7 (OMS527), which is in Phase I clinical trial for treating addiction and compulsive disorders, and movement disorders. In addition, the company's preclinical programs comprise MASP-3 (OMS906) for paroxysmal nocturnal hemoglobinuria (PNH) and other alternative pathway disorders; MASP-2-small-molecule inhibitors used for the treatment of aHUS, IgAN, HSCT-TMA, and age-related macular degeneration; and MASP-3-small-molecule inhibitors to treat PNH and other alternative pathway disorders. Further, its preclinical programs include G protein-coupled receptor (GPCR) platform, including GPR174, GPR151, GPR161, and other Class A orphan GPCRs for treating immunologic, immuno-oncologic, metabolic, CNS, cardiovascular (CV), musculoskeletal, and other disorders; and antibody platform for metabolic, CV, oncologic, musculoskeletal, and other disorders. The company was incorporated in 1994 and is headquartered in Seattle, Washington.
Read More
Omeros logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.3Community Rank: 2.9Dividend Strength: 0.0Insider Behavior: 0.8Valuation: 0.0 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.41 out of 5 stars


Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
Current SymbolNASDAQ:OMER
CUSIP68214310
Phone206-676-5000
Employees258

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$111.81 million
Book Value($2.19) per share

Profitability

Net Income$-84,490,000.00
Net Margins-107.65%

Miscellaneous

Market Cap$709.61 million
Next Earnings Date3/1/2021 (Estimated)
OptionableOptionable
$11.51
-0.23 (-1.96 %)
(As of 11/30/2020 03:50 PM ET)
30 days | 90 days | 365 days | Advanced Chart

Receive OMER News and Ratings via Email

Sign-up to receive the latest news and ratings for OMER and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles











Omeros (NASDAQ:OMER) Frequently Asked Questions

How has Omeros' stock been impacted by COVID-19 (Coronavirus)?

Omeros' stock was trading at $15.04 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, OMER stock has decreased by 24.6% and is now trading at $11.34.
View which stocks have been most impacted by COVID-19
.

Do Wall Street analysts recommend investors buy shares of Omeros?

5 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Omeros in the last year. There are currently 2 hold ratings and 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
View analyst ratings for Omeros
or view MarketBeat's top 5 stock picks.

What stocks does MarketBeat like better than Omeros?

Wall Street analysts have given Omeros a "Buy" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's winning trading ideas this year have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Omeros wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

When is Omeros' next earnings date?

Omeros is scheduled to release its next quarterly earnings announcement on Monday, March 1st 2021.
View our earnings forecast for Omeros
.

How were Omeros' earnings last quarter?

Omeros Co. (NASDAQ:OMER) announced its quarterly earnings results on Saturday, November, 14th. The biopharmaceutical company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.50) by $0.16.
View Omeros' earnings history
.

What price target have analysts set for OMER?

5 brokers have issued 12 month target prices for Omeros' shares. Their forecasts range from $12.00 to $32.00. On average, they expect Omeros' share price to reach $21.25 in the next twelve months. This suggests a possible upside of 87.4% from the stock's current price.
View analysts' price targets for Omeros
.

Who are some of Omeros' key competitors?

What other stocks do shareholders of Omeros own?

Who are Omeros' key executives?

Omeros' management team includes the following people:
  • Dr. Gregory A. Demopulos, Co-Founder, Chairman, CEO & Pres (Age 61, Pay $813.81k)
  • Mr. Michael A. Jacobsen, Chief Accounting Officer, VP of Fin. & Treasurer (Age 62, Pay $369.95k)
  • Mr. Peter B. Cancelmo J.D., VP, Gen. Counsel & Corp. Sec. (Age 41, Pay $307.91k)
  • Dr. Pamela Pierce Palmer, Co-Founder (Age 57)
  • Dr. George A. Gaitanaris M.D., Ph.D., Chief Scientific Officer & VP of Science (Age 63)
  • Mr. Peter W. Williams, VP of HR
  • Dr. J. Steven Whitaker, VP of Clinical Devel. & Chief Medical Officer (Age 64)
  • Dr. Catherine A. Melfi, Chief Regulatory Officer & VP of Regulatory Affairs and Quality Systems (Age 61)
  • Mr. Daniel G. Kirby, Chief Commercial Officer, VP & Head of Commercial (Age 48)

What is Omeros' stock symbol?

Omeros trades on the NASDAQ under the ticker symbol "OMER."

Who are Omeros' major shareholders?

Omeros' stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (8.97%), State Street Corp (2.22%), Cpwm LLC (1.10%), Consonance Capital Management LP (0.79%), Morgan Stanley (0.72%) and Charles Schwab Investment Management Inc. (0.64%).
View institutional ownership trends for Omeros
.

Which major investors are selling Omeros stock?

OMER stock was sold by a variety of institutional investors in the last quarter, including Consonance Capital Management LP, State Street Corp, CAPROCK Group Inc., Wells Fargo & Company MN, Cypress Capital Group, Cpwm LLC, Nwam LLC, and Calton & Associates Inc..
View insider buying and selling activity for Omeros
.

Which major investors are buying Omeros stock?

OMER stock was purchased by a variety of institutional investors in the last quarter, including BlackRock Inc., Morgan Stanley, Empire Life Investments Inc., Charles Schwab Investment Management Inc., Squarepoint Ops LLC, Capital Analysts LLC, Cubist Systematic Strategies LLC, and Bourgeon Capital Management LLC.
View insider buying and selling activity for Omeros
.

How do I buy shares of Omeros?

Shares of OMER can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Omeros' stock price today?

One share of OMER stock can currently be purchased for approximately $11.34.

How big of a company is Omeros?

Omeros has a market capitalization of $699.13 million and generates $111.81 million in revenue each year. The biopharmaceutical company earns $-84,490,000.00 in net income (profit) each year or ($0.96) on an earnings per share basis. Omeros employs 258 workers across the globe.

What is Omeros' official website?

The official website for Omeros is www.omeros.com.

How can I contact Omeros?

Omeros' mailing address is 201 ELLIOT AVENUE WEST, SEATTLE WA, 98119. The biopharmaceutical company can be reached via phone at 206-676-5000.

This page was last updated on 11/30/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.